Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMB303
- Development stage
- Preclinical
- Lead developer
- Aimed Bio
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMB303 is a ROR1-targeted antibody-drug conjugate (ADC) being co-developed by Aimed Bio and GeneQuantum Healthcare. The molecule is designed to treat various solid tumors, including lung cancer, breast cancer, and ovarian cancer, by specifically targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). AMB303 utilizes the AMB402 camptothecin payload, which acts as a topoisomerase I inhibitor to induce DNA damage and apoptosis in tumor cells upon internalization. The development of AMB303 involves a strategic partnership with Samsung Biologics for manufacturing and co-development. As of late 2023, the program is in the IND-enabling phase, moving toward clinical evaluation.
- Other names
- AMB303AMB-303AMB 303
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on AMB303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMB303.